Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 3/20 | 0.49 |
| ▸ | CFD | P00746 | 1/20 | 0.47 |
| ▸ | NOS1 | P29475 | 5/20 | 0.46 |
| ▸ | NOS2 | P35228 | 5/20 | 0.46 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.46 |
| ▸ | NOS3 | P29474 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | HTR6 | P50406 | 1/20 | 0.44 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.42 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.42 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.42 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.42 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.42 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.42 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7875006 | 0.98 | LOXL2 (0.47) | LOXL2CFDNOS1NOS2ENPP2 | |
| SCHEMBL5078291 | 0.86 | NOS1 (0.49) | NOS1NOS2NOS3HTR6SIGMAR1 | |
| SCHEMBL6678310 | 0.84 | LOXL2 (0.55) | LOXL2CFDNOS1NOS2ENPP2 | |
| SCHEMBL7865754 | 0.84 | PDK1 (0.51) | ENPP2ALDH1A1SMN1; SMN2CYP3A4SIGMAR1 | |
| SCHEMBL14367988 | 0.84 | SIGMAR1 (0.54) | ALDH1A1SMN1; SMN2SIGMAR1GRIN2DGRIN3B | |
| SCHEMBL7874966 | 0.83 | CYP3A4 (0.51) | NOS1NOS2NOS3ALDH1A1CYP3A4 | |
| SCHEMBL6676819 | 0.83 | LOXL2 (0.46) | LOXL2CFDNOS1NOS2ENPP2 | |
| Hydrochloric Acid SCHEMBL6680642 | 0.82 | LOXL2 (0.53) | LOXL2CFDNOS1NOS2ENPP2 | |
| SCHEMBL2545099 | 0.82 | ALDH1A1 (0.61) | LOXL2CFDALDH1A1SMN1; SMN2 | |
| SCHEMBL7874969 | 0.82 | NOS1 (0.46) | NOS1NOS2NOS3SMN1; SMN2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE37438-E1 | Acetamidine derivatives and their use as inhibitors for the nitric oxide synthase | GLAXO WELLCOME INC. | 2001-11-06 | — | — | US | claimed |
| US-5866612-A | Acetamidine derivatives and their use as inhibitors for the nitric oxide synthase | GLAXO WELLCOME INC. (US) | 1999-02-02 | — | — | US | claimed |
| EP-0799191-A1 | ACETAMIDINE DERIVATIVES AND THEIR USE AS INHIBITORS FOR THE NITRIC OXIDE SYNTHASE | THE WELLCOME FOUNDATION LIMITED (GB) | 1997-10-08 | — | — | EP | claimed |
| WO-1996019440-A1 | ACETAMIDINE DERIVATIVES AND THEIR USE AS INHIBITORS FOR THE NITRIC OXIDE SYNTHASE | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-06-27 | — | — | WO | claimed |
| US-20080070952-A1 | Inhibition or Treatment of Dyskinesia | PROXIMAGEN LTD., (GB) | 2008-03-20 | — | — | US | disclosed |
| EP-1850838-A2 | INHIBITION OR TREATMENT OF DYSKINESIA | Proximagen Ltd. (GB) | 2007-11-07 | — | — | EP | disclosed |
| WO-2006087577-A2 | INHIBITION OR TREATMENT OF DYSKINESIA | PROXIMAGEN LTD. (GB) | 2006-08-24 | — | — | WO | disclosed |
| US-RE37438-E1 | Acetamidine derivatives and their use as inhibitors for the nitric oxide synthase | GLAXO WELLCOME INC. | 2001-11-06 | — | — | US | disclosed |
| US-5866612-A | Acetamidine derivatives and their use as inhibitors for the nitric oxide synthase | GLAXO WELLCOME INC. (US) | 1999-02-02 | — | — | US | disclosed |
| EP-0799191-A1 | ACETAMIDINE DERIVATIVES AND THEIR USE AS INHIBITORS FOR THE NITRIC OXIDE SYNTHASE | THE WELLCOME FOUNDATION LIMITED (GB) | 1997-10-08 | — | — | EP | disclosed |
| WO-1996019440-A1 | ACETAMIDINE DERIVATIVES AND THEIR USE AS INHIBITORS FOR THE NITRIC OXIDE SYNTHASE | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070952-A1 | Inhibition or Treatment of Dyskinesia | DBH, COMT, DDO | LOXL2 1719/4885CFD 4774/4885NOS1 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.